Expands development of novel GBS vaccine in older adult population Targeting significant and growing unmet medical need of GBS infection Copenhagen, Denmark, 17 April 2023 – MinervaX ApS, a privately held Danish biotechnology company developing a novel vaccine against Group B Streptococcus (GBS), announces the first phase 1 clinical study in older adults of its […]
BioInnovation Institute (BII), an international non-profit foundation incubating and accelerating world-class life science research, today announces this year’s winners of the BII & Science Prize for Innovation. Grand Prize Winner, Dr Jordan Squair of the Swiss Federal Institute of Technology, recognized for his research into neuroprosthetic technologies Finalist, Dr Samuel Bakhoum of the Memorial Sloan Kettering Cancer […]
Alentis Therapeutics is a clinical-stage biotech developing breakthrough treatments for organ fibrosis and Claudin-1 (CLDN1) positive tumors Funding to advance clinical development of two first-in-class anti-CLDN1 antibodies and the platform to engineer CLDN1 antibody drug conjugates (ADC) and bi-specific antibodies Series C led by Jeito Capital together with Novo Holdings and RA Capital Management Naveed […]
Exclusive North American partnering deal worth up to $570m plus royalties secured for NTCD-M3 Phase 3 development plans finalised for XF-73 nasal following scientific advice from FDA and EMA XF-73 dermal commenced clinically enabling safety study sponsored by US Government’s NIAID New XF research projects initiated in cystic fibrosis and oral mucositis Leadership strengthened with appointment of […]
Data demonstrate that uPARAP is widely expressed at high levels across multiple sarcoma subtypes Strong overexpression in tumors combined with low expression levels in normal human tissues makes uPARAP an attractive candidate for therapeutic targeting of sarcomas by antibody-drug conjugates (ADCs) Copenhagen, Denmark, 13 April, 2023 – Adcendo ApS (“Adcendo”), a biotech company focused on the […]
